Models for studying benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 1, 2000, Pages 28-33

  Mahapokai, W ^a,b   Van Sluijs, F J ^a   Schalken, J A ^a,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b KHON KAEN UNIVERSITY   (Thailand)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Benign prostatic hyperplasia; In vitro; In vivo; Models

Indexed keywords

CHIMPANZEE; DISEASE MODEL; DOG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; REVIEW; TRANSGENIC MOUSE; XENOGRAFT;

EID: 0033853448     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500391     Document Type: Review

References (94)

1. Population-based studies of he epidemiology of benign prostatic hyperplasia
2. Benign prostatic hyperplasia: An overview
3. Laser prostatectomy. Long-term follow-up of 303 patients
4. Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment
5. Side-firing neodymium: YAG laser prostatectomy
6. Interstitial laser prostatectomy
7. Urolase v ultraline fibers in laser prostatectomy: 3-year follow-up of a randomized study
8. Application of the holmium: YAG laser for prostatectomy
9. High-energy transurethral microwave thermo-therapy in patients with acute urinary retention due to benign prostatic hyperplasia
10. Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: Results in 134 patients after 1 y
11. Long-term follow-up of transurethral microwave thermotherapy
12. A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermo-therapy for treatment of benign prostatic hyperplasia: Two-year follow-up
13. Why is transurethral microwave thermotherapy (TUMT) positively effective?
14. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: A single-institution experience
15. Intraprostatic temperature monitoring during transurethral microwave thermo-therapy for the treatment of benign prostatic hyperplasia
16. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia
17. Medical therapy and quality of life
18. Comparative study of therapeutic effect of dibenyline, tinasteride, and combination drugs for symptomatic benign pro-static hyperplasia
19. The chimpanzee as a model of human benign prostatic hyperplasia
20. Normal and benign human prostatic epithelial in culture
21. Primary cultures of human prostatic epithelial cell from transurethral resection specimens
22. Serial propagation of adult human prostatic epithelial cell with cholera toxin
23. Serial culture of adult human prostatic epithelial cells
24. Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates
25. Inhibition of prostatic epithelial cell proliferation by a factor secreted specifically by prostatic stromal cells
26. A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates
27. Studies on the proliferation, secretory activities, and epidermal growth factor receptor expression in benign prostatic hyperplasia explant cultures
28. Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: Oestrogen regulation of the androgen receptor
29. Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers
30. Characterization of a stromal cell model of the human benign and malignant prostate from explant culture
31. Hormone-induced morphogenesis and growth: Role of mesenchymal-epithelial interactions
32. Role of epithelial-stromal interactions in the central of gene expression in the prostate: A hypothesis
33. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase
34. Development and charaterization of nontu-morigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate
35. Nonsteroidal serum factors involved in the regulation of the proliferation of canine prostatic epithelial cell in cultures
36. Requirements for attachment and subsequent growth of canine prostatic epithelial cells in culture
37. The isolation and characterization of epithelial cells from canine prostate
38. Influence of hormone application by subcutaneous injections or steroid-containing silastic implants on human benign hyperplastic prostate tissue transplanted into male nude mice
39. Microautoradiographic studies on distribution of 5 alpha-dihydrotestosterone, cyproterone acetate and oestradiol-17 beta in human prostatic hyperplasia tissue transplanted to juvenile rats
40. 125l labeled monoclonal antibody against gamma seminoprotein in the nude mice bearing human benign prostatic hyperplasia xenografts
41. Transplantation of human benign hyperplastic prostate tissue into nude mice: First results of systemic therapy
42. Xenografts of human benign prostatic hyperplasia tissues in the nude mouse
43. The int-2 gene product acts as an epithelial growth factor in transgenic mice
44. Ruling narrows US view of animal patents
45. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model
46. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adrenocarcinoma in transgenic mice
47. Transgenic mice overexpression the prolactin gene develop dramatic enlargement of the prostate gland
48. Evidence that insulin-like growth factor 1 and growth hormone are required for prostate gland development
49. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture
50. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains
51. Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat
52. Chronology and urodynamic characterization of micturition in neurohormonally induced experimental prostate growth in the rat
53. A new mouse model fpr prostatic hyperplasia: Induction of adult prostatic overgrowth by fetal urogenital sinus implants
54. Tissue interactions and prostatic growth: II. Morphological and biochemical characterization of adult mouse prostatic hyperplasia induced by fetal urogenital sinus implants
55. Characterization of fetal urogenital sinus-induced prostatic hyperplasia in the mouse: Time course, hormonal requirement, age dependency, and responsiveness of various adult organs to growth induction by fetal urogenital sinus tissues
56. Comparative pathology of benign prostatic hyperplasia and prostate cancer
57. The anatomic heterogeneity of the prostate
58. The induction of prostatic hyperplasia in the dog with androstanediol
59. 5α-androstan-3α, 17β-diol is a hormone: Stimulation of cAMP accumulation in human and dog prostate
60. Dose-dependent hormonal induction of benign prostatic hyperplasia (BPH) in castrated dogs
61. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia
62. Study of prostatic disease in dogs: 177 Cases (1981-1986)
63. A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy
64. Development of canine benign prostatic hyperplasia with age
65. Age-related changes in the prostate and testes of the beagles dog
66. The pathophysiology of benign prostatic hyperplasia
67. Spontaneous benign prostatic hyperplasia in the beagle: Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate
68. Common characteristics of human and canine benign prostatic hyperplasia
69. 5 alpha-reductase activity of prostate from intact and castrated dogs treated with androstenedione, the aromatase inhibitor 1-methyl-1-1, 4-andros-tadiene-3, 17-dione, and cyproterone acetate
70. Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders
71. Adenocarcinoma of the canine prostate: Immunohistochemical examination for secretory antigens
72. Dog prostate arginine esterase is related to human prostate specific antigen
73. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia
74. DNA synthesis in the canine prostate: Effects of androgen and estrogen treatment
75. Quantitative changes in the morphology of the aging canine prostate
76. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia
77. Aromatase inhibition in the dog II. Effect on growth, function, and pathology of the prostate
78. Inhibitory influence of a new steroidal anti-androgen, TZP-4238, on prostatic hyperplasia in the beagle dog
79. Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate
80. Effects of oral administration of chlormadinone acetate on canine prostatic hypertrophy
81. Visual laser ablation of the canine prostate with a diffusing fiber and an 805-nanometer diode laser
82. Laser therapy in dogs and humans - Is there a difference?
83. Benign prostatic hyperplasia: US-guided transrectal urethral enlargement with radio frequency - Initial results in a canine model
84. Holmium:Yttrium-aluminum-garnet laser prostatectomy
85. Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations
86. Ultrastructural study in canine prostatic hyperplasia - Effect of antiandrogen
87. Ablation of canine prostate using transurethral intraprostatic absolute ethanol injection
88. The prostate of the nonhuman primate: Normal anatomy and pathology
89. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog
90. Phenotypic modulation of the canine prostate after long-term treatment with androgens and estrogens
91. Light-microscopic stereologic analysis of spontaneous and steroid-induced canine prostatic hyperplasia
92. Role of the pituitary gland in experimental hormonal induction and prevention of benign prostatic hyperplasia in the dog
93. Effects of the new steroidal antiandrogen TZP-4238 on hormone-induced canine prostatic hyperplasia
94. Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5α-dihydrotestosterone and 17β-estradiol